AVE 0.00% 0.2¢ avecho biotechnology limited

cornerstone investors, page-16

  1. 5,797 Posts.
    lightbulb Created with Sketch. 736
    Have to agree Jeep. All a bit of a smoke screen.

    Funding requirements are prevelant in most or all companies that are not commercial yet. Funny about that.

    It's a natural progression, and sure the aim would be to aquire funds and be less diluted as possible before you become self sustaining.

    But to me it's what is behind the company you're investing in. Yes management is important, yes financial competancy is neccessary. No one disputes that. BUT - if what you're nuturing is a "blood diamond" than the rest will fall by the way side.
    You invest in POH because of TPM and it's pipeline. You invest in POH because when oxy and AOD and vaccines and insulin have been partnered out, we can just find the next group of actives to enhance with TPM, and then the next.

    So bring on how ever the funding comes, because when these deals start rolling in, it will seem laughable the debates we've been having.
 
watchlist Created with Sketch. Add AVE (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.